Genenta Science, a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta’s ongoing clinical programs.    “The expansion of our existing relationship with AGC Biologics underscores the progress of our platform’s clinical development. Bas...